http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Hesham Ziglam ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Hepatitis C Virus Genotypes and Subtypes Circulating in Libya
( Aisha Busife ),( Hesham Ziglam ),( Abdulaziz Zorgani ),( Muhammed Elhadi ),( Hazem Ahmed ),( Ahmed Elhadi ),( Najib Sufya ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Hepatitis C virus (HCV) infection is a global important health issue affecting around 150-170 million patients around the world, around 1-1.3% of the Libyan population are affected by HCV. HCV genotyping plays an important role in the clinical decision and epidemiological studies; there are six major genotypes worldwide. The aim of the study was to establish the local genotypic profile and characterize the associated treatment response rate for patients on pegylated interferon and ribavirin in Tripoli Center Hosptial (TCH) Tripoli, Libya. Methods: A total of 72 patients with a measurable serum HCV-RNA were enrolled between 2014 and 2015. HCV Genotyping was performed by the Abbott Real-Time HCV assay v2.0 using Applied Biosystem Real-Time PCR. Results: HCV with genotype 4 forms the highest incidence rate of infection, presented with 41.6%, followed by 1a (9.7%), 2 (9.7%) and 1b (6.9%). While other HCV genotype 1 and genotype 3 subtypes were detected in (27.7%). The HCV genotype 1b had achieved SVR with higher rate representing 100% of the treatment more than that of the HCV genotype 1a that displayed 28%. In contrast, the HCV genotype 3a infected patients had succeeded to achieve the SVR (100%) than other HCV genotype 3 subtypes. However, HCV genotype 2 have fully achieved the ETR with a rate of 100%. Conclusions: The sustained virological response rate with different HCV genotypes was indeed 92%, 73%, 57% and 50% of patients infected with HCV genotypes 3, 4, 2 and 1 respectively. This would reflect that the screening for HCV genotyping predicting the treatment response. Nevertheless, the HCV genotype 1a displayed the minimum level of the SVR. These results were consistent with previous reports.
-
( Aisha Busife ),( Hesham Ziglam ),( Abdulaziz Zorgani ),( Muhammed Elhadi ),( Hazem Ahmed ),( Ahmed Elhadi ),( Najib Sufya ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The global prevalence rate of hepatitis C virus (HCV) infection is 2.5 %. Approximately 21.3 million patients infected with HCV are living in Eastern Mediterranean countries. Chronic HCV patients taking interferon with ribavirin from different ethnic groups have different probabilities of reaching a sustained virological response (SVR). There are many factors, such as HCV genotype, age, gender, body weight, IL-28B single-nucleotide polymorphism, concomitant disease and liver function enzymes. The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors. Methods: Total of 120 subjects was interviewed and was subjective to routine laboratory investigation and abdominal ultrasound. Forty-six were excluded due to co-infection with HBC or HIV, decompensated liver disease, drug dependence, alcoholic, autoimmune disease, pregnancy, cardiac disease, age above 70 years, and poorly controlled diabetic patients. Only 72 patients with chronic HCV who received pegylated interferon and ribavirin (Peg-IFN/RBV) in Tripoli Center Hospital (TCH) in Tripoli, Libya from 2014 to 2015 were included. Quantitative HCVRNA was assessed before the treatment and at week 1, week 4, week12, week 24, week 48 and week 72 to detect whether the patient achieved SVR. Multivariate logistic regression analysis was performed to identify variables associated with treatment response. Results: At 24 weeks after the end of combination therapy, the overall SVR was detected in 49 (68%). However, 53 (73%) of patients achieved end treatment response (ETR). Moreover, the SVR was significantly higher in patients with genotype 1b and 3a (100%) than in patients with genotype 1a and 2 (28% and 57.1% respectively). However, there was no significant difference between patients who given INFa2a and INF a2b (P=0.75). IL28B CC haplotype patient, the viral load less than 600,000 IU.ml-1(matches 5.7 logs) and the body weight < 80kg, non-detectable HCV-RNA level at week four, and genotype of the HCV were factors that predict good response for Peg-IFN/RBV combined therapy (P<0.05). However, age and gender were not a significant predictive factor. Conclusions: This prediction model uses easily determined variables for a personalized estimate of the probability of SVR with Peg-IFN/RBV, allowing to identify patients who may benefit from conventional therapy.
-
( Aisha Busife ),( Hesham Ziglam ),( Abdulaziz Zorgani ),( Muhammed Elhadi ),( Hazem Ahmed ),( Ahmed Elhadi ),( Najib Sufya ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The Single-nucleotide polymorphism in interleukin genes have been reported to be associated with clearance of HCV and sustained virologic response (SVR). Interleukin 28B (IL28B) gene polymorphism is responsible for immune protection against viruses. IL28B gene polymorphism in HCV infection determines the fate of infection toward spontaneous clearance or chronic infection. This study aims to determine that IL28B gene polymorphism is associated with HCV clearance as well as response to interferon treatment in Libyan patient. Methods: Total of 72 patients with chronic HCV infection who received interferon plus ribavirin combination therapy were enrolled in the study. Viral RNA was checked at one, the third and sixth month of treatment. Genotyping of single-nucleotide polymorphism (SNP) rs12979860 of IL-28B gene was performed using DNA isolated from blood plasma. Detection was performed using Applied Biosystem® Real-Time PCR. Results: Twenty-four patients (33%) had CC genotype, 36 (50%) had CT, and 12 (17%) had TT. CC patients obviously had achieved the SVR (91%) more than that of CT/TT (58% and 50%) respectively (P<0.005). This had reported with HCV genotype 1 and HCV genotype 4 infected patients similar to other findings reported by several studies. The studied patients who have infected with HCV genotype 3 had achieved RVR and succeeded to achieve the SVR irrespective of their IL28B genotypes where the relapse there after had reported only with the CC patients. On the other hand, CC/TT (haplotype) patients infected with HCV genotype 2 significantly achieved the RVR that eventually translate to SVR achievement. However, the rate of the RVR for CT patients was indeed lower that consequently translated into a lower SVR rate and higher of the thereafter relapse. IL28B CC genotype was the independent predictive factor for SVR with an (odds ratio [OR] 10.59; (95% confidence interval [CI]: 1.47-76.43; P=0.019). These findings were indeed consistent with several studies using the IL28B with various genotypes as predictive factors for the SVR. Conclusions: The CC patients showed a trend toward higher viral decline more than the CT and TT patients. Therefore, IL28B genotyping may be used as a predictor of IFN-based therapy outcomes, and a strategy for developing personalized treatment of hepatitis C patients in Libya.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
